Your browser doesn't support javascript.
loading
A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies.
How, Joan; Ren, Siyang; Lombardi-Story, Jennifer; Bergeron, Meghan; Foster, Julia; Amrein, Phillip C; Brunner, Andrew M; Fathi, Amir T; Hock, Hanno; Khachatryan, Anna; Kikuchi, Hiroto; Ng, Mei Rosa; Moran, Jenna; Narayan, Rupa; Neuberg, Donna; Ramos, Aura; Som, Tina; Vartanian, Meghan; Chen, Yi-Bin; Duda, Dan G; Hobbs, Gabriela S.
Afiliación
  • How J; Division of Hematology Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USA.
  • Ren S; Department of Data Sciences Dana-Farber Cancer Institute Boston Massachusetts USA.
  • Lombardi-Story J; Department of Medical Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
  • Bergeron M; Department of Medical Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
  • Foster J; Department of Medical Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
  • Amrein PC; Department of Medical Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
  • Brunner AM; Department of Medical Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
  • Fathi AT; Department of Medical Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
  • Hock H; Department of Medical Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
  • Khachatryan A; Department of Radiation Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
  • Kikuchi H; Department of Radiation Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
  • Ng MR; Department of Radiation Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
  • Moran J; Department of Medical Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
  • Narayan R; Department of Medical Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
  • Neuberg D; Department of Data Sciences Dana-Farber Cancer Institute Boston Massachusetts USA.
  • Ramos A; Department of Medical Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
  • Som T; Department of Medical Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
  • Vartanian M; Department of Medical Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
  • Chen YB; Department of Medical Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
  • Duda DG; Department of Radiation Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
  • Hobbs GS; Department of Medical Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
EJHaem ; 3(2): 434-442, 2022 May.
Article en En | MEDLINE | ID: mdl-35846042

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: EJHaem Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: EJHaem Año: 2022 Tipo del documento: Article